id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
aiua-12833	AlShoaibi, Ismaeel; Abdo, Basheer; Abdullah, Mohammed; Alzanen, Khaled; Alhakamy, Mohammed; Al-Namer, Mamoon; Al-Hagri, Abdulghani; Salah, Morshed; Salem, Afrah; Almogahed, Mohammed; Alnadhari, Ibrahim; Ahmed, Faisal	Effect of DOPA decarboxylase inhibitor supplements on the incidence of urinary tract infections in Parkinson’s disease patients: A systematic review and meta-analysis of randomized controlled trials	2024	10	.pdf	application/pdf	5749	302	56	D Author Year of Year of starting Intervention Consumption Country Sample Follow-up publication data collection or control form size time 1 Chung, et al (20) 2022 - Levadopa+Carbidopa Intestinal gel 9 sites in Spain, 8 sites in the United States, 7 sites in Italy, 87 26 weeks 4 sites in Australia, 3 sites in Canada, 3 sites in the Republic of Korea, 2 sites in Greece, 1 site in Germany, 1 site in Sweden 1 Chung, et al (20) 2022 - Other Tablet or capsule 9 sites in Spain, 8 sites in the United States, 7 sites in Italy, 87 26 weeks 4 sites in Australia, 3 sites in Canada, 3 sites in the Republic of Korea, 2 sites in Greece, 1 site in Germany, 1 site in Sweden 2 Fahn, et al (21) 2004 1998 Levadopa+Carbidopa Tablet 33 sites in the United States and 5 sites in Canada 361 40 weeks 2 Fahn, et al (21) 2004 1998 Other Tablet 33 sites in the United States and 5 sites in Canada 361 40 weeks 3 Freire-Alvarez, et al (22) 2021 - Levadopa+Carbidopa Intestinal gel 9 sites in Spain, 5 sites in Italy, 4 sites in Slovakia, 3 sites 61 12 weeks in Hungary, 3 sites in Greece, 2 sites in the United States, 2 sites in Finland 3 Freire-Alvarez, et al (22) 2021 - Other Tablet or capsule 9 sites in Spain, 5 sites in Italy, 4 sites in Slovakia, 3 sites 61 12 weeks in Hungary, 3 sites in Greece, 2 sites in the United States, 2 sites in Finland 4 Hauser, et al (23) 2013 2009 Levadopa+Carbidopa Tablet 35 sites in the United States, 7 sites in Ukraine, 7 sites 393 22 weeks (extended-release) in Poland, 6 sites in Spain, 6 sites in Germany, 5 sites in France, 4 sites in Romania, 3 sites in Canada 4 Hauser, et al (23) 2013 2009 Levadopa+Carbidopa Tablet 35 sites in the United States, 7 sites in Ukraine, 393 22 weeks (immediate release) 7 sites in Poland, 6 sites in Spain, 6 sites in Germany, 5 sites in France, 4 sites in Romania, 3 sites in Canada 5 Hauser, et al (24) 2023 2018 Levadopa+Carbidopa Tablet 56 sites in the United States, 15 sites in Spain, 8 sites 506 20 weeks (extended-release) in Germany, 8 sites in Italy, 7 sites in Poland, 7 sites In Poland, 6 sites in Czechia, 6 sites in Germany, 5 sites in France, 3 sites in the United Kingdom 5 Hauser, et al (24) 2023 2018 Levadopa+Carbidopa Tablet 56 sites in the United States, 15 sites in Spain, 8 sites 506 20 weeks (immediate release) in Germany, 8 sites in Italy, 7 sites in Poland, 7 sites In Poland, 6 sites in Czechia, 6 sites in Germany, 5 sites in France, 3 sites in the United Kingdom 6 Olanow, et al (25) 2004 - Levadopa+Carbidopa Tablet multicenter 750 26 weeks 6 Olanow, et al (25) 2004 - Other Tablet multicenter 750 26 weeks 7 Rascol, et al (26) 2016 2012 Levadopa+Carbidopa Tablet 10 sites in the United States, 3 sites in Poland, 2 sites 68 12 weeks in Slovakia, 1 site in Germany 7 Rascol, et al (26) 2016 2012 Other Tablet 10 sites in the United States, 3 sites in Poland, 2 sites 68 12 weeks in Slovakia, 1 site in Germany 8 Schapira, et al (27) 2017 2009 Levadopa+Carbidopa Tablet / Tablet 28 sites in the United States, 12 sites in Germany, 12 sites 549 24 weeks and/or in Hungary, 8 sites in India, 6 sites in Israel, 6 sites in Slovakia, Levadopa+ Benserazide 6 sites in Canada, 6 sites in Belgium, 5 sites in Thailand, 5 sites in the United Kingdome, 5 sites in France, 4 sites in Spain, 3 sites in the Republic of Korea, 3 sites in Taiwan, 3 sites in New Zealand, 2 sites in Australia, 2 sites in Austria, 2 sites in Malaysia, 2 sites in Switzerland, 1 site in Estonia, 1 site in the Netherlands 8 Schapira, et al (27) 2017 2009 Other Tablet 28 sites in the United States, 12 sites in Germany, 12 sites 549 24 weeks in Hungary, 8 sites in India, 6 sites in Israel, 6 sites in Slovakia, 6 sites in Canada, 6 sites in Belgium, 5 sites in Thailand, 5 sites in the United Kingdome, 5 sites in France, 4 sites in Spain, 3 sites in the Republic of Korea, 3 sites in Taiwan, 3 sites in New Zealand, 2 sites in Australia, 2 sites in Austria, 2 sites in Malaysia, 2 sites in Switzerland, 1 site in Estonia, 1 site in the Netherlands 9 Stocchi, et al (28) 2010 - Levadopa+Carbidopa Tablet 31 sites in the United States, 6 sites in Italy, 5 sites in Germany, 744 134 weeks 5 sites in Finland, 4 sites in Sweden, 4 sites in France, 4 sites in the United Kingdom, 4 sites in Canada, 2 sites in Greece, 2 sites in Belgium, 2 sites in Spain, 2 sites in Switzerland, 1 site in Australia, 1 site in Turkey 9 Stocchi, et al (28) 2010 - Other Tablet 31 sites in the United States, 6 sites in Italy, 5 sites in Germany, 744 134 weeks 5 sites in Finland, 4 sites in Sweden, 4 sites in France, 4 sites in the United Kingdom, 4 sites in Canada, 2 sites in Greece, 2 sites in the Belgium, 2 sites in the Spain, 2 sites in the Switzerland, 1 site in the Australia, 1 site in the Turkey Archivio Italiano di Urologia e Andrologia 2024; 96(4):12833 5 DOPA decarboxylase inhibitors and risk of urinary tract infections in Parkinson’s disease FIgure 2. Risk of Bias Assessment: (A) Risk of bias summary of all included randomized clinical trials (RCTs); (B) Detailed risk of bias.	cache/aiua-12833.pdf	txt/aiua-12833.txt